Tags:BioTechClinicDesignDevelopmentDiagnosticsDrugIndustryInterestLearnPharmacyPlatformServiceTechnologyTools
ImmunoScape enables the characterization of a patient’s immune profile at unprecedented resolution. Our assays provide a view into the immune system in action, directly observing T cell phenotype & function with simultaneous tracking of TCR-antigen binding. Our platform delivers key insights on antigen-specific T cells in studies of immune checkpoint blockade, therapeutic and prophylactic vaccines, and T cell therapy, empowering researchers and drug developers. Discover novel vaccine, antibody, or cell therapy targets Evaluate treatment outcomes through longitudinal studies Design successful clinical trials through efficient patient enrollment Uncover combinations of predictive biomarkers of disease or treatment efficacy Demonstrate proof-of-mechanism in tissues of interest To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
Likes
493
Location: Singapore, Singapore
Member count: 11-50
Total raised: $25M

Investors 2

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
14.04.2021-$14M--
11.08.2020-$11MAnzu Partn...-

Mentions in press and media 114

DateTitleDescriptionCategoryAuthorSource
29.04.2021ImmunoScap...ImmunoScape, a biotech company...--sdbj.com/n...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
14.04.2021ImmunoScap...---connect.or...
Show more